Cadrenal Therapeutics (CVKD) said Tuesday it has signed a collaboration agreement with Abbott (ABT) to support a trial of its tecarfarin anticoagulation and hemocompatibility with left ventricular assist devices.
Financial terms were not disclosed.
Under the terms of the agreement, Abbott will support Cadrenal on the planning and execution of the trial to evaluate the efficacy and safety of tecarfarin in patients with left ventricular assist devices.
Abbott will also share insights from recent trials and will support Cadrenal with trial design, site identification, trial awareness, and expertise.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。